Evidence map›Paper›PMID 36614224›Full record

ReviewInternational journal of molecular sciences2023

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments.

Karolina Makowska, Joanna Nowaczyk, Leszek Blicharz, Anna Waśkiel-Burnat, Joanna Czuwara, Małgorzata Olszewska, Lidia Rudnicka

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Patient Stratification for Serum LDH Levels Reveals Distinct CLAInternational journal of molecular sciences · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Karolina MakowskaDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.ORCID 0000-0001-9091-9181
Joanna NowaczykDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.ORCID 0000-0001-7438-3559
Leszek BlicharzDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.ORCID 0000-0002-7633-4168
Anna Waśkiel-BurnatDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.
Joanna CzuwaraDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.
Małgorzata OlszewskaDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.
Lidia RudnickaDepartment of Dermatology, Medical University of Warsaw, 02-008 Warsaw, Poland.
Medical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease.

Indexed as

Dermatitis, AtopicSkin DiseasesHumansInterleukinsPruritusSkinInterleukinsatopic dermatitisbiological treatmentbiologicscytokinesendotypesinterleukinsJAK inhibitorspathogenesisphenotypessmall molecules

Identifiers

PMID36614224
PMCPMC9820829
OpenAlexW4313471582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.